BLN-481 not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Part 1 (SAD): Single IV doses in Cohorts 1A-1E at planned doses of 10, 30, 100, 300, and 900 mg. Optional Cohort 1X may receive a single IV or SC dose; optional Cohorts 1Y and 1Z may receive a single SC dose, with dose levels to be determined. Each Part 1 cohort includes up to 8 participants randomized 6:2 to BLN-481: placebo. Part 2 (MAD): SC dosing in Cohort 2A at 50 mg Q2W, Cohort 2B at 150 mg…”In the company’s words, NCT07903064 on ClinicalTrials.gov
- Main trialPhase 1
- “This Phase 1 first-in-human study will evaluate BLN-481 in healthy adults. Participants will receive BLN-481 or placebo. Part 1 evaluates single ascending intravenous (IV) doses (SAD) and optional subcutaneous (SC) doses. Part 2 evaluates multiple ascending subcutaneous doses (MAD). The main purpose is to assess safety and tolerability. The study will also evaluate how BLN-481 moves through the body, whether anti-drug antibodies (ANA) develop, and pharmacodynamic (PD) effects.”In the company’s words, NCT07903064 on ClinicalTrials.gov
Coming up1
- 24 Nov 2027Phase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07903064
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 24 Nov 2027 | A Phase 1, First-in-Human Trial of BLN-481in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026